Cargando…

Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention

BACKGROUND: Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) may be a potential biomarker of coronary artery disease (CAD) and stroke. OBJECTIVE: We aimed to investigate the association and prognostic value of elevated sLOX-1 concentrations with regard to long-term major adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zi-wen, Xu, Yi-wei, Li, Shu-mei, Guo, Jin-jian, Sun, Jian-min, Hong, Ju-chang, Chen, Liang-long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854229/
https://www.ncbi.nlm.nih.gov/pubmed/31772687
http://dx.doi.org/10.1155/2019/4925767
_version_ 1783470185743646720
author Zhao, Zi-wen
Xu, Yi-wei
Li, Shu-mei
Guo, Jin-jian
Sun, Jian-min
Hong, Ju-chang
Chen, Liang-long
author_facet Zhao, Zi-wen
Xu, Yi-wei
Li, Shu-mei
Guo, Jin-jian
Sun, Jian-min
Hong, Ju-chang
Chen, Liang-long
author_sort Zhao, Zi-wen
collection PubMed
description BACKGROUND: Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) may be a potential biomarker of coronary artery disease (CAD) and stroke. OBJECTIVE: We aimed to investigate the association and prognostic value of elevated sLOX-1 concentrations with regard to long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with CAD undergoing primary percutaneous coronary intervention (PCI). METHODS: A total of 1011 patients were enrolled. Serum sLOX-1 concentrations were detected by the enzyme-linked immunosorbent assay (ELISA). Patients were followed for 2 years. Multivariate Cox regression and Kaplan-Meier survival curve were explored to assess the association between sLOX-1 and MACCEs. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of sLOX-1. RESULTS: Two-year MACCEs were associated with serum sLOX-1 concentrations (HR 1.278, 95% CI 1.019-1.604, P = 0.034), left main disease (HR 2.938, 95% CI 1.246-6.925, P = 0.014), small-caliber stents used (HR 2.207, 95% CI 1.189-4.095, P = 0.012), and total stent length (HR 1.057, 95% CI 1.005-1.112, P = 0.030). Serum sLOX-1 concentration ≥ 1.10 ng/ml had maximum sensitivity and specificity in predicting the occurrence of 2-year MACCEs (P < 0.001). Patients with higher serum sLOX-1 concentrations showed a significantly higher incidence of MACCEs in the Kaplan-Meier curve (P < 0.001). The combination of any of the risk factors identified in multiple Cox regression was associated with a stepwise increase in MACCE rate (P < 0.001). CONCLUSIONS: High baseline serum sLOX-1 concentration predicts 2-year MACCEs and shows an additional prognostic value to conventional risk factors in patients after primary PCI. sLOX-1 determination might play a complementary role in the risk stratification of patients with CAD treated with PCI.
format Online
Article
Text
id pubmed-6854229
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68542292019-11-26 Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention Zhao, Zi-wen Xu, Yi-wei Li, Shu-mei Guo, Jin-jian Sun, Jian-min Hong, Ju-chang Chen, Liang-long Dis Markers Research Article BACKGROUND: Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) may be a potential biomarker of coronary artery disease (CAD) and stroke. OBJECTIVE: We aimed to investigate the association and prognostic value of elevated sLOX-1 concentrations with regard to long-term major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with CAD undergoing primary percutaneous coronary intervention (PCI). METHODS: A total of 1011 patients were enrolled. Serum sLOX-1 concentrations were detected by the enzyme-linked immunosorbent assay (ELISA). Patients were followed for 2 years. Multivariate Cox regression and Kaplan-Meier survival curve were explored to assess the association between sLOX-1 and MACCEs. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of sLOX-1. RESULTS: Two-year MACCEs were associated with serum sLOX-1 concentrations (HR 1.278, 95% CI 1.019-1.604, P = 0.034), left main disease (HR 2.938, 95% CI 1.246-6.925, P = 0.014), small-caliber stents used (HR 2.207, 95% CI 1.189-4.095, P = 0.012), and total stent length (HR 1.057, 95% CI 1.005-1.112, P = 0.030). Serum sLOX-1 concentration ≥ 1.10 ng/ml had maximum sensitivity and specificity in predicting the occurrence of 2-year MACCEs (P < 0.001). Patients with higher serum sLOX-1 concentrations showed a significantly higher incidence of MACCEs in the Kaplan-Meier curve (P < 0.001). The combination of any of the risk factors identified in multiple Cox regression was associated with a stepwise increase in MACCE rate (P < 0.001). CONCLUSIONS: High baseline serum sLOX-1 concentration predicts 2-year MACCEs and shows an additional prognostic value to conventional risk factors in patients after primary PCI. sLOX-1 determination might play a complementary role in the risk stratification of patients with CAD treated with PCI. Hindawi 2019-10-20 /pmc/articles/PMC6854229/ /pubmed/31772687 http://dx.doi.org/10.1155/2019/4925767 Text en Copyright © 2019 Zi-wen Zhao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhao, Zi-wen
Xu, Yi-wei
Li, Shu-mei
Guo, Jin-jian
Sun, Jian-min
Hong, Ju-chang
Chen, Liang-long
Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title_full Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title_fullStr Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title_full_unstemmed Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title_short Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
title_sort baseline serum slox-1 concentrations are associated with 2-year major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854229/
https://www.ncbi.nlm.nih.gov/pubmed/31772687
http://dx.doi.org/10.1155/2019/4925767
work_keys_str_mv AT zhaoziwen baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT xuyiwei baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT lishumei baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT guojinjian baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT sunjianmin baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT hongjuchang baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention
AT chenlianglong baselineserumslox1concentrationsareassociatedwith2yearmajoradversecardiovascularandcerebrovasculareventsinpatientsafterpercutaneouscoronaryintervention